Loading...
NPI 1962485136 · Ankeny, IA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Central Iowa Hospital Corporation is a clinical medical laboratory provider located in Ankeny, Iowa. This profile covers 304 Medicare and 222 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Central Iowa Hospital Corporation |
| Address | 3001 Se Convenience Blvd Unit 104 |
| City | Ankeny |
| State | IA |
| ZIP | 50021 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 22, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $26.7M |
| Medicare | $3M |
CENTRAL IOWA HOSPITAL CORPORATION is effectively Medicaid‑centric by scale: reported Medicare revenue is $3M versus Medicaid revenue of $26.7M, indicating the vast majority of billed volume and dollars come from Medicaid payers rather than Medicare. This payer mix suggests contracts and operational focus are likely oriented toward state programs and high Medicaid throughput.
Revenue concentration is moderate but meaningful on both payers: the top 3 Medicare codes account for 29.7% of Medicare revenue while the top 3 Medicaid codes account for 32.1% of Medicaid revenue. On Medicare the highest single-code contributors visible in the file include 80061 ($240.1K, 11.8%), 84443 ($190.5K, 9.4%), and 80053 ($174.4K, 8.6%), whereas on Medicaid the largest contributors include U0003 ($3.3M, 17.3%), 87491 ($1.4M, 7.4%), and 87591 ($1.4M, 7.4%).
The code mix reflects a high‑throughput clinical laboratory with strong molecular and infectious disease testing capabilities: large Medicaid volumes for molecular SARS‑CoV‑2 testing (U0003, 42.1K claims) and multiplex respiratory testing (0202U, 3.4K claims) coexist with high volumes of STD nucleic acid tests (87491 and 87591, each ~44K claims). Routine chemistry and hematology panels (80053, 80061, 85025) and specimen collection (36415) at scale on both payers indicate integrated phlebotomy and automated lab processing.
Competitively in its state, the lab is a dominant player for many routine and molecular tests: multiple Medicaid codes rank #1 in‑state (for example U0003 ranks #1 of 64 providers in-state, 87491 and 87591 rank #1 in-state) and are labeled “extreme outlier, far above typical state volume,” which signals market leadership in Medicaid molecular and screening services. That statewide dominance for high‑revenue Medicaid codes likely translates into substantial referral volume from clinics and public health programs.
On the Medicare side the provider shows nationally strong participation for many common lab codes: several Medicare codes (for example 80061 ranks #102 of 21671; 84443 ranks #123 of 19722; 80053 ranks #141 of 26416) sit at very high national percentiles and are described as typical or unremarkable volume for those codes, while 80048 is flagged as an “extreme outlier, far above typical national volume” (rank #53 of 14725). Additionally, 86832 and 86833 appear among a small set of national providers (each rank #3 of 22) performing specialized HLA solid‑phase assays, indicating capability in lower‑volume, higher‑complexity immunogenetics testing.
The provider reports several explicit statistical outliers across payers that inform operational risk and capacity: on Medicaid multiple high‑revenue codes are labeled “extreme outlier, far above typical state volume” (for example U0003, 87491, 87591, 87636, 88175), while on Medicare specific codes like 80048 are likewise flagged as “extreme outlier, far above typical national volume.” These outlier labels imply unusually large state or national shares for particular tests and suggest the lab is configured to handle very high specimen throughput for those services.
CENTRAL IOWA HOSPITAL CORPORATION’s long tenure in the NPI registry (enumerated 2005-11-22, ~21 years ago) supports the view that these volumes reflect an established laboratory operation rather than a newly scaled service line. That longevity, combined with the breadth of routine panels, molecular PLA codes (e.g., 0202U), and specialized assays, points to sustained investment in both instrumentation and workflow to serve large Medicaid contracts.
Operationally, the combination of very high claim counts for routine collection and panels (Medicaid claims counts such as 66.5K for 85025 and 65.8K for 80053; Medicare counts such as 18.6K for 80048 and 17.4K for 80053) together with high‑value PLA and multiplex molecular codes (0202U, U0003, 87636) indicates a high‑throughput, automated lab model that handles both large volume screening and higher‑complexity molecular testing. This mix suggests the provider is positioned to capture volume across preventive screening, infectious disease diagnostics, and routine clinical chemistry for its regional referral base.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
304 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 18,470 | $10 | $240.1K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 11,900 | $20 | $190.5K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 17,440 | $10 | $174.4K |
| 80048 | The lab analyst performs a basic metabolic pane (BMP) test in which he measures the blood level of eight chemicals including total calcium, sodium, potassium, chloride, carbon dioxide, glucose, blood… | 18,590 | $10 | $148.7K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 17,010 | $10 | $136.1K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 3,700 | $30 | $107.3K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 12,560 | $10 | $100.4K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 710 | $140 | $99K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 9,060 | $10 | $81.5K |
| 86832 | The lab analyst performs a solid phase immunoassay using patient serum to identify the presence of specific antibodies to specific Class I human leukocyte antigens, or HLA, using a high–definition… | 240 | $320 | $74K |
Showing 1–10 of 304
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 304 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
222 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 42,060 | $80 | $3.3M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 44,470 | $30 | $1.4M |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 44,420 | $30 | $1.4M |
| 0202U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0202U for the… | 3,410 | $380 | $1.3M |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 10,940 | $120 | $1.3M |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 41,500 | $20 | $954.5K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 2,610 | $360 | $945.6K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 19,660 | $50 | $904.5K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 52,330 | $10 | $732.6K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 22,050 | $30 | $639.5K |
Showing 1–10 of 222
How this provider's Medicaid billing volume and revenue compare to other Iowa providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Iowa median
222 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 1 | 10 | 330 | $360 | $286.9K |
| 0202U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0202U for the… | 4 | 50 | 130 | $320 | $224.4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 60 | 210 | $80 | $186.8K |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 1 | 20 | 660 | $20 | $104.8K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 1 | 30 | 150 | $110 | $96.1K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 26 | 30 | 200 | $110 | $85.8K |
| 0241U | N/A | 5 | 80 | 290 | $110 | $85.1K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 1 | 20 | 890 | $30 | $80.7K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 1 | 60 | 320 | $30 | $72.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 1 | 60 | 300 | $30 | $71.8K |
Showing 1–10 of 222
Other providers in the same ZIP code as Central Iowa Hospital Corporation, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Purfoods, LLC | IA | Home Delivered Meals | $0 | $902.3M |
| Ankeny Smiles, LLC | IA | Dentist | $0 | $3.8M |
| Mercy Clinics, Inc | IA | Primary Care Clinic/Center | $0 | $1.5M |
| Mark Isaacson | IA | Orthopaedic Surgery Physician | $335.5K | $0 |
| Guardian Pharmacy Of Iowa LLC | IA | Long Term Care Pharmacy | $309.1K | $13.6K |
| Catholic Health Initiatives-iowa Corp | IA | Diagnostic Radiology Physician | $150.3K | $19.4K |
| Bryan Trout | IA | Foot & Ankle Surgery Podiatrist | $121.3K | $0 |
| Grx Holdings, LLC | IA | Community/Retail Pharmacy | $109K | $7K |
| David Harrison | IA | Family Medicine Physician | $115.9K | $0 |
| Ricardo Bendezu | IA | Family Medicine Physician | $84.4K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.